Finance

Lists
BIOA:NASDAQ
BIOAGE Labs Inc
USD 10,60
+1,63%
(+0,17) 1D
USD 10,60
0,00% (0,00)
After hours
Closed: 14 Aug., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIOA...
Open
USD 10,37
High
USD 10,63
Low
USD 10,10
Mkt. cap
486,51 m
Avg. vol.
1,10 m
Volume
444,37 k
52-wk high
USD 25,96
52-wk low
USD 4,38
EPS
-USD 2,39
Shares outstanding
45,90 m
No. of employees
61
Open
USD 10,37
High
USD 10,63
Low
USD 10,10
Mkt. cap
486,51 m
Avg. vol.
1,10 m
Volume
444,37 k
52-wk high
USD 25,96
52-wk low
USD 4,38
EPS
-USD 2,39
Shares outstanding
45,90 m
No. of employees
61
News stories
From web sources and news partners
About BIOAGE Labs Inc
CEO-
Employees61
Founded2015
HeadquartersEmeryville, Kalifornië, Verenigde State van Amerika
SectorPharmaceutical industry
Websitebioagelabs.com
Analyst ratings
Based on 9 analysts giving stock ratings to BIOA in the past 3 months
Strong buy
Buy
7
Hold
2
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for BIOA in the last 3 months.
Highest
Current USD 10,60
USD 73,00 (+588,68%)
Average
USD 35,63 (+236,13%)
Lowest
USD 20,00 (+88,68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Michael Ulz
Morgan Stanley
Hold
Maintained
USD 20,00
+88,7%
08/07/2026
Adam Walsh
Roth MKM
Buy
Maintained
USD 25,00
+135,8%
08/07/2026
Jay Olson
Oppenheimer
Buy
Maintained
USD 50,00
+371,7%
08/06/2026
Joseph Stringer
Needham
Buy
Maintained
USD 35,00
+230,2%
08/06/2026
Samantha Semenkow
Citi
Buy
Maintained
USD 21,00
+98,1%
08/06/2026
Andy Hsieh
William Blair
Hold
Reiterated
-
-
08/06/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
USD 73,00
+588,7%
08/06/2026
Thomas Shrader
BTIG
Buy
Maintained
USD 40,00
+277,4%
08/05/2026
Roger Song
Jefferies
Buy
Maintained
USD 21,00
+98,1%
07/31/2026
Last report
05 Aug. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-USD 0,58 / -USD 0,62
+7,09%beat
Revenue / Est. (USD)
2,45 m / 1,50 m
+63,65%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
2,05 m
3,08 m
2,77 m
2,45 m
Cost of goods sold
18,51 m
24,50 m
20,41 m
24,36 m
Cost of revenue
18,51 m
24,50 m
20,41 m
24,36 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6,68 m
7,00 m
7,74 m
7,42 m
Operating expense
6,68 m
7,00 m
7,74 m
7,42 m
Total operating expenses
25,19 m
31,50 m
28,15 m
31,78 m
Operating income
-23,14 m
-28,42 m
-25,38 m
-29,33 m
Other non operating income
-42,00 k
-220,00 k
-107,00 k
-201,00 k
EBT including unusual items
-20,17 m
-25,94 m
-22,25 m
-26,10 m
EBT excluding unusual items
-20,17 m
-25,94 m
-22,25 m
-26,10 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-20,17 m
-25,94 m
-22,25 m
-26,10 m
Net profit margin
-982,03%
-842,85%
-802,78%
-1 064,75%
Earnings per share
-0,56
-0,72
-0,52
-0,58
Interest and investment income
3,16 m
2,79 m
3,27 m
3,44 m
Interest expense
-149,00 k
-92,00 k
-39,00 k
-1,00 k
Net interest expenses
3,01 m
2,70 m
3,23 m
3,44 m
Depreciation and amortization charges
-
-
-
-
EBITDA
-23,09 m
-28,35 m
-25,31 m
-29,26 m
Gain or loss from assets sale
-
23,00 k
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme